Zhongsheng Pharmaceutical announced that the clinical trial of RAY1225 injection, an innovative polypeptide drug independently developed by the holding subsidiary Zhongsheng Ruichuang, was approved by the State Drug Administration and received a “Drug Clinical Trial Approval Notice” to conduct clinical trials with additional indications for RAY1225 injection.

Zhongsheng Pharmaceutical announced that the clinical trial of RAY1225 injection, an innovative polypeptide drug independently developed by the holding subsidiary Zhongsheng Ruichuang, was approved by the State Drug Administration and received a “Drug Clinical Trial Approval Notice” to conduct clinical trials with additional indications for RAY1225 injection.